Maze Therapeutics (MAZE) Depreciation & Amortization (CF) (2024 - 2026)

Maze Therapeutics' Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $444000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 35.09% to $444000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.2 million, a 28.71% decrease, with the full-year FY2025 number at $2.4 million, down 27.18% from a year prior.
  • Depreciation & Amortization (CF) hit $444000.0 in Q1 2026 for Maze Therapeutics, down from $499000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for MAZE hit a ceiling of $950000.0 in Q1 2024 and a floor of $444000.0 in Q1 2026.
  • Historically, Depreciation & Amortization (CF) has averaged $683000.0 across 3 years, with a median of $684000.0 in 2025.
  • Biggest five-year swings in Depreciation & Amortization (CF): fell 24.0% in 2025 and later tumbled 35.09% in 2026.
  • Tracing MAZE's Depreciation & Amortization (CF) over 3 years: stood at $708000.0 in 2024, then dropped by 29.52% to $499000.0 in 2025, then decreased by 11.02% to $444000.0 in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for MAZE at $444000.0 in Q1 2026, $499000.0 in Q4 2025, and $571000.0 in Q3 2025.